Share Price:

APNASPENAspen Pharmacare Hldgs19559156 (0.80%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Regional Overviews

Aspen in Africa Middle East

The Africa Middle East region comprises 45 countries and ranks as the second-largest revenue contributor by region in the Group. Its commercial and sales teams support both local and international brands, each with robust brand equity, within the Commercial Pharmaceuticals segment, which contributes 22% of total revenue.


One of the Group‘s strategic manufacturing sites is located in Gqeberha, South Africa, and has extensive capabilities in high-potency and hormonal solids, vaccines, and advanced sterile technologies. South Africa also hosts two additional regional manufacturing sites in Cape Town and East London, while further sites in Ghana, Kenya, and Tanzania all contribute to the region’s manufacturing strength.

Key Countries

Egypt
Kingdom of Saudi Arabia
South Africa
Tanzania
Kenya

Overview

Brand Therapeutic category

Imuran

Immunosuppressant

Mara Moja

Analgesic anti-inflammatory

Mybulen

Analgesic anti-inflammatory

Stilpane

Narcotic analgesic combinations

Trustan

Anti-ulcerant

10
Products
Launched

(2022: 25)

0
Product
Recalls

(2022: 1)

0 %
Average Staff
Turnover

(2022: 13%)

Work-related
Facilities

(2022: Nil)

100
Sales
Representatives

(2022: 218)

2500
Permanent
Employees

(June 2022: 3,945)

Revenue 2023
R’million
2022 (CER)
R’million
Change
%

Commercial Pharmaceuticals

8 154

8 523

(4)

Regional Brands

7 711

7 983

(3)

Sterile Focus Brands

443

540

18

Manufacturing

646

2 051

>100

API Chemicals

192

229

(16)

FDF - Other

11

22

(50)

FDF - Steriles

443

1 800

(75)

Total

8 800

10 574

(17)

Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture.

Contribution to Group revenue (%)
Revenue by segment (%)

Source: IQVIA June 2023. Sources: IQVIA TPM Moving Annual Total June 2022, IQVIA Middle East & Africa Pharmaceutical Market Insights. Released June 2022.
* Moving annual total (“MAT”).

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.